Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Prostatic Neoplasms 14Neoplasm Metastasis 3Prostate Cancer Metastatic 1Neoplasms 1Metastatic Castration-resistant Prostate Cancer 1Metastatic Castration-Resistant Prostate Cancer (mCRPC) 1Metastatic Castrate-resistant Prostate Cancer 1Castrate Refractory Metastatic Prostate Cancer (mCRPC) 1

Interventions

Radiosurgery 5Androgen Antagonists 4enzalutamide 2Prednisone 2Docetaxel 2talazoparib 1sipuleucel-T 1rucaparib 1olaparib 1gallium 68 PSMA-11 1darolutamide 1cabazitaxel 1apalutamide 1XRP6258 1Radiotherapy, Image-Guided 1Radiotherapy 1Positron Emission Tomography Computed Tomography 1Pluvicto 1Lutetium-177 1Lutetium 1Lenograstim 1Hematologic Tests 1Granulocyte Colony-Stimulating Factor 1Gonadotropin-Releasing Hormone 1Abiraterone Acetate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Prostate Cancer Metastatic × sipuleucel-T × Clear all
NCT03024216 2021-05-26

Clinical Study of Atezolizumab (Anti-PD-L1) and Sipuleucel-T in Patients With Asymptomatic or Minimally Symptomatic Metastatic Castrate Resistant Prostate Cancer

University of Hawaii

Phase 1 Completed
37 enrolled
Genitourinary

Prostate Cancer Metastatic

Data powered by HemOnc (CC BY 4.0) Colophon âš¡